What is Gilvetmab?: An Innovative Immunotherapy for Canine Cancer
•
4 min read
According to research, mast cell tumors account for approximately 20% of all skin cancers in dogs, making them one of the most common malignancies in canines. The arrival of groundbreaking immunotherapies like **Gilvetmab** offers a new and promising approach to treating these tumors and other forms of canine cancer.
